Die Wechselwirkung Mit Ribosomalen Proteinen Begleitet Die Stressinduktion Des Wirkstoffkandidaten BOLD-100/KP1339 Im Endoplasmatischen Retikulum

Overview

Journal Angew Chem Weinheim Bergstr Ger

Date 2024 Mar 20

PMID 38505777

Authors

Benjamin Neuditschko

Anton A Legin

Dina Baier

Arno Schintlmeister

Siegfried Reipert

Michael Wagner

Bernhard K Keppler

Walter Berger

Samuel M Meier-Menches

Christopher Gerner

Affiliations

Soon will be listed here.

Citing Articles

Die Wechselwirkung mit ribosomalen Proteinen begleitet die Stressinduktion des Wirkstoffkandidaten BOLD-100/KP1339 im endoplasmatischen Retikulum.

Neuditschko B, Legin A, Baier D, Schintlmeister A, Reipert S, Wagner M Angew Chem Weinheim Bergstr Ger. 2024; 133(10):5121-5126.

PMID: 38505777 PMC: 10947255. DOI: 10.1002/ange.202015962.

Highly Cytotoxic Molybdenocenes with Strong Metabolic Effects Inhibit Tumour Growth in Mice.

Fuchs V, Cseh K, Hejl M, Vician P, Neuditschko B, Meier-Menches S Chemistry. 2022; 29(4):e202202648.

PMID: 36222279 PMC: 10099754. DOI: 10.1002/chem.202202648.

References

Hong M, Lin M, Huang J, Baumeister P, Hakre S, Roy A . Transcriptional regulation of the Grp78 promoter by endoplasmic reticulum stress: role of TFII-I and its tyrosine phosphorylation. J Biol Chem. 2005; 280(17):16821-8. DOI: 10.1074/jbc.M413753200. View

Meier-Menches S, Zappe K, Bileck A, Kreutz D, Tahir A, Cichna-Markl M . Time-dependent shotgun proteomics revealed distinct effects of an organoruthenium prodrug and its activation product on colon carcinoma cells. Metallomics. 2018; 11(1):118-127. DOI: 10.1039/c8mt00152a. View

Burris H, Bakewell S, Bendell J, Infante J, Jones S, Spigel D . Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort. ESMO Open. 2017; 1(6):e000154. PMC: 5548977. DOI: 10.1136/esmoopen-2016-000154. View

Bytzek A, Koellensperger G, Keppler B, Hartinger C . Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action. J Inorg Biochem. 2016; 160:250-5. DOI: 10.1016/j.jinorgbio.2016.02.037. View

Babak M, Meier S, Huber K, Reynisson J, Legin A, Jakupec M . Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action. Chem Sci. 2018; 6(4):2449-2456. PMC: 5647740. DOI: 10.1039/c4sc03905j. View

Shannon P, Markiel A, Ozier O, Baliga N, Wang J, Ramage D . Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13(11):2498-504. PMC: 403769. DOI: 10.1101/gr.1239303. View

Hu D, Yang C, Lok C, Xing F, Lee P, Fung Y . An Antitumor Bis(N-Heterocyclic Carbene)Platinum(II) Complex That Engages Asparagine Synthetase as an Anticancer Target. Angew Chem Int Ed Engl. 2019; 58(32):10914-10918. DOI: 10.1002/anie.201904131. View

Wernitznig D, Kiakos K, Del Favero G, Harrer N, Machat H, Osswald A . First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro. Metallomics. 2019; 11(6):1044-1048. DOI: 10.1039/c9mt00051h. View

Fung S, Zou T, Cao B, Lee P, Fung Y, Hu D . Cyclometalated Gold(III) Complexes Containing N-Heterocyclic Carbene Ligands Engage Multiple Anti-Cancer Molecular Targets. Angew Chem Int Ed Engl. 2017; 56(14):3892-3896. DOI: 10.1002/anie.201612583. View

10.

Blazevic A, Hummer A, Heffeter P, Berger W, Filipits M, Cibin G . Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse. Sci Rep. 2017; 7:40966. PMC: 5256101. DOI: 10.1038/srep40966. View

11.

Legin A, Schintlmeister A, Jakupec M, Galanski M, Lichtscheidl I, Wagner M . NanoSIMS combined with fluorescence microscopy as a tool for subcellular imaging of isotopically labeled platinum-based anticancer drugs. Chem Sci. 2022; 5(8):3135-3143. PMC: 9273000. DOI: 10.1039/c3sc53426j. View

12.

Meier-Menches S, Gerner C, Berger W, Hartinger C, Keppler B . Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development. Chem Soc Rev. 2017; 47(3):909-928. DOI: 10.1039/c7cs00332c. View

13.

Cetinbas N, Webb M, Dubland J, Walsby C . Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR. J Biol Inorg Chem. 2009; 15(2):131-45. DOI: 10.1007/s00775-009-0578-5. View

14.

Misra U, Wang F, Pizzo S . Transcription factor TFII-I causes transcriptional upregulation of GRP78 synthesis in prostate cancer cells. J Cell Biochem. 2008; 106(3):381-9. DOI: 10.1002/jcb.22016. View

15.

Legin A, Theiner S, Schintlmeister A, Reipert S, Heffeter P, Jakupec M . Multi-scale imaging of anticancer platinum(iv) compounds in murine tumor and kidney. Chem Sci. 2018; 7(5):3052-3061. PMC: 6004953. DOI: 10.1039/c5sc04383b. View

16.

Parker R, Phan T, Baumeister P, Roy B, Cheriyath V, Roy A . Identification of TFII-I as the endoplasmic reticulum stress response element binding factor ERSF: its autoregulation by stress and interaction with ATF6. Mol Cell Biol. 2001; 21(9):3220-33. PMC: 86961. DOI: 10.1128/MCB.21.9.3220-3233.2001. View

17.

Wang H, Zhou Y, Xu X, Li H, Sun H . Metalloproteomics in conjunction with other omics for uncovering the mechanism of action of metallodrugs: Mechanism-driven new therapy development. Curr Opin Chem Biol. 2020; 55:171-179. DOI: 10.1016/j.cbpa.2020.02.006. View

18.

Flocke L, Trondl R, Jakupec M, Keppler B . Molecular mode of action of NKP-1339 - a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines. Invest New Drugs. 2016; 34(3):261-8. PMC: 4859864. DOI: 10.1007/s10637-016-0337-8. View

19.

Bijelic A, Theiner S, Keppler B, Rompel A . X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism. J Med Chem. 2016; 59(12):5894-903. PMC: 4921950. DOI: 10.1021/acs.jmedchem.6b00600. View

20.

Heffeter P, Bock K, Atil B, Hoda M, Korner W, Bartel C . Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. J Biol Inorg Chem. 2010; 15(5):737-48. PMC: 3371400. DOI: 10.1007/s00775-010-0642-1. View